CinRx teams with Sam Waksal's Graviton on ROCK2 for PAH, other cardio conditions

Sam Waksal is doubling down on ROCK2 after his first work on the target led to the chronic graft-versus-host disease medicine Rezurock. Now, the Graviton Bioscience CEO is teaming up with a cardio drug development ...